Arbutus Biopharma Corp
ABUSNext catalyst
Imdusiran (AB-729)
Chronic Hepatitis B
Get an email about ABUS's next catalysts
Track Arbutus Biopharma (ABUS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
ABUS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
Imdusiran (AB-729) Phase 2 Est. Readout (i-LIVER)
Estimated primary completion for Imdusiran (AB-729) trial (NCT06154278) in Chronic Hepatitis B. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
WebsiteTKM-080301
Cancer
ARB-001467
Hepatitis B, Chronic
AB-729
Chronic Hepatitis b
Imdusiran (AB-729)
Chronic Hepatitis B
Peg-IFNα-2a
Chronic Hepatitis b
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TKM-080301 | Phase 2 | Cancer | - | - |
ARB-001467 | Phase 2 | Hepatitis B, Chronic | - | - |
AB-729 | Phase 2 | Chronic Hepatitis b | - | - |
Imdusiran (AB-729) | Phase 2 | Chronic Hepatitis B | - | - |
Peg-IFNα-2a | Phase 2 | Chronic Hepatitis b | - | - |
Cancer
1 drug in this indication
Chronic Hepatitis b
1 drug in this indication
Hepatitis B, Chronic
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Arbutus Biopharma Corp's drug pipeline?→
CatalystAlert tracks 5 drug candidates in Arbutus Biopharma Corp's (ABUS) pipeline across Phase 2. Its lead program is Imdusiran (AB-729) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arbutus Biopharma Corp's next FDA catalyst?→
Arbutus Biopharma Corp's (ABUS) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ABUS biotech catalysts?→
Add ABUS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arbutus Biopharma Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.